Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86

Sijie Yang¹, Yuanling Yu², Fanchong Jian³, Weiliang Song⁴, Ayijiang Yisimayi⁴, Xiaosu Chen⁵, Yanli Xu⁶, Peng Wang², Jing Wang², Lingling Yu², Xiao Niu⁷, Jing Wang⁴, Tianhe Xiao⁸, Ran An², Yao Wang², Qingqing Gu², Fei Shao², Ronghua Jin⁶, Zhongyang Shen⁹, Youchun Wang¹⁰, Yunlong Cao¹¹

Affiliations

¹ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Peking-Tsinghua Centre for Life Sciences, Tsinghua University, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁴ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁵ Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, China.
⁶ Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁷ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China.
⁸ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
⁹ Organ Transplant Centre, National Health Commission Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
¹⁰ Changping Laboratory, Beijing, China; Institute of Medical Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China.
¹¹ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 37738994
DOI: 10.1016/S1473-3099(23)00573-X

Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86

Sijie Yang et al. Lancet Infect Dis. 2023 Nov.

. 2023 Nov;23(11):e457-e459.

doi: 10.1016/S1473-3099(23)00573-X. Epub 2023 Sep 19.

Authors

Affiliations

¹ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Peking-Tsinghua Centre for Life Sciences, Tsinghua University, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁴ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁵ Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, China.
⁶ Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁷ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China.
⁸ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
⁹ Organ Transplant Centre, National Health Commission Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
¹⁰ Changping Laboratory, Beijing, China; Institute of Medical Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China.
¹¹ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 37738994
DOI: 10.1016/S1473-3099(23)00573-X

No abstract available

PubMed Disclaimer

Conflict of interest statement

YC applied for a provisional patent for BD series antibodies, which includes BD55–5514 (SA55), and is the founder of Singlomics Biopharmaceuticals. All other authors declare no competing interests.

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86

Affiliations

Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86

Authors

Affiliations

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous